Sponsored Links
| CEL-SCI Commences Phase III Clinical Trial In Head And Neck Cancer In Hungary |
 |
 |
 |
| Medical News - Cancer Oncology | |||
|
CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India... Read more: Cancer / Oncology News From Medical News Today
|